Clinical Trial: XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07688577) titled 'XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors' on June 22.

Brief Summary: This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Metastatic NSCLC - Non-Small Cell Lung Cancer Advanced Solid Tumor

Intervention: DRUG: XTX501

XTX501 monotherapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Xilio Development, Inc.

Published by HT Digit...